GVHD
Published on November 12, 2024
Treating GVHD with CD3×CD3 BsAb
by Blood Advances
Espinosa-Cotton M, Hoseini SS, Miranda IC, et al. Targeting T Cells With Tetravalent Bispecific Antibodies for the Treatment of Graft Versus Host Disease. Blood Advances. 2024; (doi: 10.1182/bloodadvances.2022009187).
Scientists believe a tetravalent bispecific antibody (BsAb) might effectively combat graft-versus-host disease (GVHD), a common complication of allogeneic hematopoietic stem cell transplantation. Picomolar concentrations of the CD3xCD3 BsAb — so called because all four binding domains are specific for CD3 — triggered robust lysis of activated CD4 and CD8 T cells. Promising results were observed in immunodeficient mouse models, with researchers reporting that 0.1 mcg BsAb per dose eradicated most T cells from the peripheral blood and 10 mcg per dose reversed confirmed GVHD, with a 100% survival rate. Mice bearing NALM6-luc xenografts were treated with CD3xCD3 BsAb, which reversed clinical evidence of GVHD. Curing GVHD makes it possible to conduct long-term follow-up of tumor response — which was not previously possibly in humanized murine models.
Read More
![]()